See more : Y.S.Food Co.,Ltd. (3358.T) Income Statement Analysis – Financial Results
Complete financial analysis of Lexaria Bioscience Corp. (LEXX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lexaria Bioscience Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Newport Gold, Inc. (NWPG) Income Statement Analysis – Financial Results
- VisasQ Inc. (4490.T) Income Statement Analysis – Financial Results
- Nextdoor Holdings, Inc. (KVSB) Income Statement Analysis – Financial Results
- Nexcom A/S (NEXCOM.CO) Income Statement Analysis – Financial Results
- Toll Brothers, Inc. (TOL) Income Statement Analysis – Financial Results
Lexaria Bioscience Corp. (LEXX)
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 464.28K | 226.21K | 255.40K | 722.74K | 384.54K | 222.61K | 433.29K | 63.64K | 40.72K | 14.70K | 1.10M | 1.36M | 1.13M | 362.47K | 421.96K | 900.79K | 253.15K | 20.31K | 20.31K |
| Cost of Revenue | 4.82K | 31.50K | 71.84K | 175.35K | 99.38K | 22.89K | 25.19K | 29.75K | 45.62K | 29.88K | 795.20K | 783.27K | 667.86K | 273.62K | 548.32K | 912.75K | 124.91K | 93.32K | 93.32K |
| Gross Profit | 459.46K | 194.71K | 183.56K | 547.39K | 285.17K | 199.72K | 408.10K | 33.89K | -4.90K | -15.18K | 302.25K | 574.49K | 465.91K | 88.86K | -126.37K | -11.96K | 128.24K | -73.01K | -73.01K |
| Gross Profit Ratio | 98.96% | 86.07% | 71.87% | 75.74% | 74.16% | 89.72% | 94.19% | 53.25% | -12.03% | -103.26% | 27.54% | 42.31% | 41.09% | 24.51% | -29.95% | -1.33% | 50.66% | -359.55% | -359.55% |
| Research & Development | 2.36M | 3.67M | 1.84M | 1.26M | 387.07K | 555.73K | 492.86K | 54.19K | 9.02K | 146.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.85M | 3.06M | 5.72M | 4.97M | 3.57M | 3.13M | 6.02M | 1.63M | 1.01M | 1.49M | 1.27M | 561.89K | 678.09K | 466.67K | 458.04K | 475.34K | 1.01M | 121.44K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 204.28K | 515.36K | 489.06K | 209.03K | 185.46K | 276.56K | 8.19K | 3.47K | 40.92K | 559.00 | 930.00 | 4.11K | 20.07K | 20.07K | 0.00 |
| SG&A | 3.85M | 3.06M | 5.72M | 4.97M | 3.77M | 3.64M | 6.51M | 1.84M | 1.20M | 1.76M | 8.19K | 565.35K | 719.01K | 467.23K | 458.97K | 479.45K | 1.03M | 141.51K | 35.14K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 112.75K | 60.55K | 2.31K | -886.00 | 4.60K | -22.66K | 0.00 | 14.04K | 6.40K | 0.00 | 8.21K | 1.28K | 148.38K | -2.99K | 0.00 |
| Operating Expenses | 6.21M | 6.73M | 7.57M | 6.23M | 4.27M | 4.26M | 7.01M | 1.90M | 1.21M | 1.91M | 8.19K | 579.40K | 725.41K | 474.00K | 467.18K | 480.72K | 1.18M | 138.53K | 35.14K |
| Cost & Expenses | 6.22M | 6.76M | 7.64M | 6.41M | 4.37M | 4.28M | 7.03M | 1.92M | 1.26M | 1.94M | 803.40K | 1.36M | 1.39M | 747.61K | 1.02M | 1.39M | 1.30M | 231.85K | 35.14K |
| Interest Income | 14.31K | 43.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 94.00 | 4.09K | 18.09K | 6.12K | 6.12K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.02K | 2.25K | 31.54K | 267.36K | 246.61K | 278.73K | 167.32K | 160.12K | 857.58K | 4.71K | 21.91K | 21.91K |
| Depreciation & Amortization | 76.15K | 145.40K | 146.91K | 147.60K | 146.09K | 60.55K | 2.31K | 1.49K | 619.00 | -22.66K | 1.52M | 456.60K | 370.62K | 122.16K | 342.13K | 453.12K | 148.38K | 81.76K | 40.44K |
| EBITDA | -5.68M | -6.39M | -6.52M | -5.58M | -4.00M | -4.10M | -6.61M | -1.92M | -1.26M | -1.95M | 294.06K | -35.30K | 442.73K | 111.12K | -236.15K | -244.37K | -414.37K | -891.03K | -129.78K |
| EBITDA Ratio | -1,222.75% | -2,824.23% | -2,835.72% | -977.11% | -982.78% | -1,752.23% | -1,522.76% | -2,922.37% | -2,983.84% | -13,269.46% | 26.79% | 33.27% | 9.80% | -72.55% | -59.58% | 37.67% | -356.22% | 730.49% | 26.11% |
| Operating Income | -5.75M | -6.53M | -7.38M | -5.69M | -3.89M | -3.96M | -6.60M | -1.86M | -1.22M | -1.93M | 294.06K | -4.90K | -259.50K | -552.46K | -753.67K | -898.09K | -1.05M | -489.66K | -35.14K |
| Operating Income Ratio | -1,239.16% | -2,888.50% | -2,891.05% | -786.85% | -1,012.10% | -1,779.43% | -1,523.29% | -2,924.71% | -2,985.36% | -13,115.30% | 26.79% | -0.36% | -22.89% | -152.42% | -178.61% | -99.70% | -414.83% | -2,411.28% | -173.02% |
| Total Other Income/Expenses | -55.52K | -178.50K | -764.61K | 1.52M | 0.00 | -228.06K | -8.97K | -6.02K | -34.70K | -55.06K | -355.23K | -246.61K | -276.22K | -278.73K | 0.00 | 7.05K | -73.27K | -565.19K | -473.12K |
| Income Before Tax | -5.81M | -6.71M | -7.38M | -4.16M | -4.08M | -4.16M | -6.61M | -1.93M | -1.28M | -1.98M | -1.87M | -251.51K | -538.23K | -552.46K | -753.67K | -971.35K | -1.05M | -211.54K | -75.58K |
| Income Before Tax Ratio | -1,251.12% | -2,967.41% | -2,891.05% | -576.16% | -1,062.20% | -1,868.03% | -1,525.36% | -3,031.89% | -3,136.82% | -13,489.80% | -170.50% | -18.52% | -47.47% | -152.42% | -178.61% | -107.83% | -416.69% | -1,041.70% | -372.16% |
| Income Tax Expense | 0.00 | 0.00 | -114.33K | -1.66M | -54.29K | 39.62K | -8.97K | -54.17K | -60.23K | -181.23K | 294.06K | 246.61K | 278.73K | 167.32K | -94.00 | 7.14K | 1.04K | 574.84K | 40.59K |
| Net Income | -5.80M | -6.66M | -7.27M | -2.50M | -4.03M | -4.20M | -6.60M | -1.87M | -1.21M | -1.77M | -1.87M | -251.51K | -538.23K | -552.46K | -753.57K | -978.49K | -1.06M | -508.26K | -75.72K |
| Net Income Ratio | -1,248.25% | -2,946.36% | -2,846.28% | -346.50% | -1,048.08% | -1,885.83% | -1,522.97% | -2,937.31% | -2,983.38% | -12,042.58% | -170.50% | -18.52% | -47.47% | -152.42% | -178.59% | -108.63% | -417.10% | -2,502.87% | -372.89% |
| EPS | -0.47 | -1.01 | -1.24 | -0.57 | -1.45 | -1.62 | -2.79 | -0.95 | -0.83 | -1.34 | -0.07 | -0.42 | -1.09 | -1.22 | -2.80 | -4.46 | -5.21 | -3.16 | -1.37 |
| EPS Diluted | -0.47 | -1.01 | -1.24 | -0.57 | -1.45 | -1.62 | -2.79 | -0.95 | -0.83 | -1.34 | -0.07 | -0.42 | -1.09 | -1.22 | -2.80 | -4.46 | -5.21 | -3.16 | -1.37 |
| Weighted Avg Shares Out | 12.38M | 6.61M | 5.89M | 4.39M | 2.77M | 2.59M | 2.37M | 1.96M | 1.46M | 1.32M | 25.71M | 602.48K | 493.23K | 451.94K | 268.67K | 219.28K | 202.59K | 160.87K | 55.15K |
| Weighted Avg Shares Out (Dil) | 12.38M | 6.61M | 5.89M | 4.39M | 2.77M | 2.59M | 2.37M | 1.96M | 1.46M | 1.32M | 25.71M | 602.48K | 493.23K | 451.94K | 268.67K | 219.28K | 202.59K | 160.87K | 55.15K |
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
KELOWNA, BC / ACCESSWIRE / July 28, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has incorporated a new wholly-owned subsidiary under the name Lexaria Nutraceutical Corp. ("LEXX Nutra")....
Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
More countries are banning e-cigarettes as novel oral products gain traction KELOWNA, BC / ACCESSWIRE / July 19, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has been granted...
Why Is Lexaria Bioscience (LEXX) Stock Down 27% Today?
Lexaria Bioscience (NASDAQ: LEXX ) stock is falling on Tuesday after the company revealed details about its public share offering. According to a press release, the LEXX public stock offering will include 2,106,000 units with each one containing one share...
9 Cannabis Stocks on Fire This Week
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
Why Shares Of Lexaria Biosciences Are Trading Higher
Lexaria Bioscience Corp. (NASDAQ: LEXX) shares are trading higher after the company announced manufacturing and license agreements with BevNology. The first agreement is a manufacturing operating agreement that expands production capabilities for Lexaria's own growing list of business-to-.
Lexaria Posied To Receive US Patent For DehydraTECH To Deliver Antiviral Drugs
Lexaria Bioscience Corp (NASDAQ: LEXX) is receiving its first-ever patent for DehydraTECH technology in the enhanced delivery of antiviral drugs. Lexaria has received notification from the United States Patent and Trademark Office that patent 11,311,559 for Compositions and Methods.
Why Is Lexaria Bioscience (LEXX) Stock Up Today?
Today, investors in Lexaria Bioscience and LEXX stock are seeing impressive gains as investors price a key catalyst into shares. The post Why Is Lexaria Bioscience (LEXX) Stock Up Today?
Why Lexaria Shares Are Rising Today
Lexaria Bioscience Corp (NASDAQ: LEXX) said that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 are complete, assessing a single 300mg dose of DehydraTECH-processed cannabidiol (DehydraTECH-CBD). The study findings indicated a tendency (p=0.1).
Read Why Lexaria Bioscience Shares Are Surging During Wednesday Premarket?
Lexaria Bioscience Corp (NASDAQ: LEXX) has issued follow-up results from human clinical study HYPER-H21-2 of DehydraTECH-processed cannabidiol (CBD). The data showed that after a single day of dosing, the processed CBD reduced arterial stiffness, potentially broadening its application to the treatment of cardiovascular...
Lexaria Bioscience Stock (LEXX): Why The Price Surged Today
The stock price of Lexaria Bioscience Corp (NASDAQ: LEXX) increased by over 20% pre-market today. This is why it happened.
Source: https://incomestatements.info
Category: Stock Reports